Bankrupt ReGen Biologics Inc. (OTC:RGBO) took out a loan from a company affiliated with one of its investors. The new debt represents Regen’s second financing deal with the company since filing for Chapter 11 bankruptcy two weeks ago.
Illumina Inc.
BD profits increase 5 percent on sales growth | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Mass. Life Sciences Center doles out another $3.8 million in loans
MASSDEVICE ON CALL — The Mass. Life Sciences Center, a quasi-public agency that oversees state dollars allocated toward increasing the life sciences industry’s footprint in the Bay State, doled out another $3.8 million in “accelerator” loans.
The program is designed to provide a boost to early-stage life science companies that the center’s scientific advisory board deems to have a high potential for commercialization, rapid growth and the ability to raise substantial capital.
Steris profits dive as product shipments slow | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Maternal stroke history linked with women’s risk for heart attacks | Research roundup
Here’s a roundup of recent clinical trial and scientific study news:
Illumina’s Q2 sales, earnings rise
Second-quarter sales rose 31.2 percent and net income jumped 20.7 percent for Illumina Inc. (NSDQ:ILMN), even as the company announced its plans to get into the bench-top polymerase chain reaction business with the acquisition of Helixis Inc.
The San Diego-based genetic lab instruments maker reported net income of $29.8 million, or 21 cents per diluted share, on sales of $212.0 million during the three months ended July 4. That compares with net income of $24.7 million, or 18 cents per diluted share, on sales of $161.6 million during the three months ended June 28, 2009.
Illumina’s Q4 sales rise 10 percent but net income plummets 55 percent
Illumina Inc. (NSDQ:ILMN) posted fourth-quarter sales of $167.5 million for the three months ended Jan. 3, up 9.6 percent compared with $152.8 million during the same period last year. Net income fell 55.1 percent to $11.7 million, compared with $26.1 million during Q4 2008:
Press Release
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2009
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ:ILMN) today announced its financial results for the fourth quarter and fiscal year of 2009.
Helicos loses a lap to Illumina in race for cheap genome sequencing
Illumina Inc. (NSDQ:ILMN) put some distance between itself and its competitors this week, as it revealed equipment capable of sequencingthe human genome for less than $10,000.
The San Diego-based company unveiled its HiSeq 2000 at the annual J.P. Morgan Health Care Conference in San Francisco, where CEO Jay Flatley said a Hong Kong-based genomics institute called BGI bought 128 of the $690,000 systems, according to the Wall Street Journal.